Escobar, AlejandroReyes, FelipeAcevedo, MónicaAlonso, LuisValiente, FernandoSoto, RicardoPortillo, HugoGatica, JimenaFlores, IvánNova, EstefaníaBarrera, CarlosBono, MaríaVargas, LeonardoSimon, ValeskaLeiva, EliasVial, CeciliaHormazábal, JuanJimena, LinaValdés, DanielSandino, AnaImarai, MónicaAcuña, Claudio2023-05-022023-05-022022Escobar A, Reyes-López FE, Acevedo ML, Alonso-Palomares L, Valiente-Echeverría F, Soto-Rifo R, Portillo H, Gatica J, Flores I, Nova-Lamperti E, Barrera-Avalos C, Bono MR, Vargas L, Simon V, Leiva-Salcedo E, Vial C, Hormazabal J, Cortes LJ, Valdés D, Sandino AM, Imarai M, Acuña-Castillo C. Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group. Front Immunol. 2022 Jan 31;12:766278. doi: 10.3389/fimmu.2021.766278https://repositorio.udd.cl/handle/11447/7431CoronaVac vaccine from Sinovac Life Science is currently being used in several countries. In Chile, the effectiveness of preventing hospitalization is higher than 80% with a vaccination schedule. However, to date, there are no data about immune response induction or specific memory. For this reason, we recruited 15 volunteers without previous suspected/diagnosed COVID-19 and with negative PCR over time to evaluate the immune response to CoronaVac 28 and 90 days after the second immunization (dpi). The CoronaVac administration induces total and neutralizing anti-spike antibodies in all vaccinated volunteers at 28 and 90 dpi. Furthermore, using ELISpot analysis to assay cellular immune responses against SARS-CoV-2 spike protein, we found an increase in IFN-gamma- and Granzyme B-producing cells in vaccinated volunteers at 28 and 90 dpi. Together, our results indicate that CoronaVac induces a robust humoral immune response and cellular immune memory of at least 90 dpi.enCoronaVacSARS-CoV-2Herd immunityNeutralizing antibodiesCOVID-19VaccineImmunologicalmemoryArticlehttps://doi.org/10.3389/fimmu.2021.766278